<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591302</url>
  </required_header>
  <id_info>
    <org_study_id>46787</org_study_id>
    <nct_id>NCT03591302</nct_id>
  </id_info>
  <brief_title>Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.</brief_title>
  <official_title>Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion to Withdraw Immunosuppressive Drugs From Recipients of a Previous HLA Matched Living Donor Kidney Transplantation .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephan Busque</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine whether patients with functioning Human Leukocyte Antigen (HLA)
      matched kidney transplants for at least one year and who want to discontinue
      immunosuppressive drugs can be treated with Total Lymphoid Irradiation (TLI) and rabbit
      Anti-Thymocyte Globulin (rATG) and an HLA matched donor hematopoietic progenitor cell
      infusion such that their drugs are successfully withdrawn while maintaining normal renal
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label study in adult renal transplant patients.Twenty five
      patients with functioning HLA matched living donor kidney transplants will receive TLI, rATG
      and an infusion of cluster of differentiation (CD)34+ (Stem/Progenitor cells) selected
      granulocyte colony-stimulating factor (G-CSF) mobilized blood cells combined with CD3+ T
      cells (Stem/ Progenitor cells) from their transplant donors.Transplant recipients will have
      their maintenance Immunosuppressive drugs adjusted for four weeks before starting the TLI and
      ATG conditioning regimen. Mycophenolate Mofetil (MMF) will be maintained at 0.5 gm twice a
      day per day during this four week period during TLI and ATG treatments, and increased to 1
      gram twice a day immediately after the completion of TLI at day 14.

      MMF will be tapered starting 6 (six) months later. Tacrolimus levels will be targeted to
      blood trough levels of 4-6 ng/ml in the month before the start of the conditioning regimen.
      This target would be increased to 8-10 ng/ml at the start of the TLI and ATG conditioning
      regimen. At serial time points (1) graft function will be monitored. (2) chimerism will be
      measured in recipient white blood cell subsets, (3) protocol biopsies of the graft will be
      obtained. An attempt will be made to discontinue Tacrolimus at 12 months if (1) chimerism is
      detectable for least 180 days after the CD34+ and CD3+ cell infusion, (2) there is no Graft
      Versus Host Disease (GVHD), (3) there is stable graft function without clinical rejection
      episodes and (4) lack of histological rejection on protocol biopsies.

      Recipients will be given the target dose of ≥ 8 x 10^6 CD 34 + cells/Kg and a dose of 5x10^6
      CD3+ cells/Kg.The dose would be sequentially increased to 10, 15 and 25 x 10^6 CD3+ cells/Kg
      if fewer than 4 of 5 consecutive patients achieve whole blood chimerism of ≥ 30 % at 60 days.
      If 4 of 5 patients achieve this level of chimerism, then all subsequent enrolled patients
      will receive this dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T Cell Transfusion in previous HLA Matched Living Donor Kidney Transplantation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients no longer dependent on immunosuppressive drugs to maintain normal renal function.</measure>
    <time_frame>six months to up to five years post stem cell transplant</time_frame>
    <description>A patient will be considered no longer dependent if able to maintain normal renal function after coming off immunosuppressive medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients experiencing biopsy proven rejection episodes requiring treatment requiring corticosteroids.</measure>
    <time_frame>One year to five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients experiencing graft loss.</measure>
    <time_frame>One year to five years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Immune Tolerance</condition>
  <arm_group>
    <arm_group_label>Immune tolerance, Kidney transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: HLA matched living donor recipients of a functioning kidney transplant graft at one year will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance such as to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic cell transplantation</intervention_name>
    <description>Transplantation of hematopoietic stem cells from living donor.</description>
    <arm_group_label>Immune tolerance, Kidney transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Lymphoid irradiation</intervention_name>
    <description>Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.</description>
    <arm_group_label>Immune tolerance, Kidney transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All consenting adults of age 18 years and older with previous HLA matched sibling
             living donor renal transplants who still have their HLA- matched kidney donor
             available, and who have no history of acute or chronic rejection.

          2. Patients who agree to participate in the study and sign an Informed Consent

          3. The HLA-matched donor meets the Stanford Bone Marrow Transplant criteria for stem cell
             donation, agrees to participate and has signed an Informed Consent.

          4. The pair is confirmed to be HLA-matched (2 haplo type match) as determined by the
             histocompatibility laboratory at Stanford.

          5. Patients who have no known contraindication to the administration of rabbit ATG or
             radiation

          6. Males and females of reproductive potential who agree to practice a reliable form of
             contraception for at least 18 months post transplant.

        Exclusion Criteria:

          1. Known allergy to ATG or a known allergy to rabbit proteins.

          2. History of malignancy with the exception of non-melanoma skin malignancies.

          3. Pregnant women or nursing mothers.

          4. Serological evidence of HIV, Hepatitis B (HepBsAg+) or Hepatitis C infection.

          5. Leukopenia (with a white blood cell count &lt; 3000/mm3) or thrombocytopenia (platelet
             count &lt; 100,000/mm3)

          6. Previous history of acute or chronic rejection of the kidney transplant or recurrence
             of the original disease.

          7. Screening kidney biopsy demonstrating acute or chronic rejection, recurrence of
             original disease or interstitial fibrosis/Tubular Atrophy (IF/TA) score greater than
             1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Md Strober, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asha Shori, CCRP</last_name>
    <phone>6507360245</phone>
    <email>ashas@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Busque, MD,MS</last_name>
    <phone>6504986189</phone>
    <email>sbusque@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asha Shori, CCRP</last_name>
      <phone>650-736-0245</phone>
      <email>ashas@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Busque, MD, MS</last_name>
      <phone>650-498-6189</phone>
      <email>sbusque@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Scandling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Everett Meyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Shizuru, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Lowsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hoppe Richard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Pham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Strober, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Busque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008 Jan 24;358(4):362-8. doi: 10.1056/NEJMoa074191.</citation>
    <PMID>18216356</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med. 2011 Oct 6;365(14):1359-60. doi: 10.1056/NEJMc1107841.</citation>
    <PMID>21991976</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012 May;12(5):1133-45. doi: 10.1111/j.1600-6143.2012.03992.x. Epub 2012 Mar 8.</citation>
    <PMID>22405058</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, Jensen K, Shori A, Strober JA, Lavori P, Turnbull BB, Engleman EG, Strober S. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant. 2015 Mar;15(3):695-704. doi: 10.1111/ajt.13091.</citation>
    <PMID>25693475</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Lowsky R, Shizuru J, Shori A, Engleman E, Jensen K, Strober S. Macrochimerism and clinical transplant tolerance. Hum Immunol. 2018 May;79(5):266-271. doi: 10.1016/j.humimm.2018.01.002. Epub 2018 Jan 9. Review.</citation>
    <PMID>29330112</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Stephan Busque</investigator_full_name>
    <investigator_title>Professor for Surgery</investigator_title>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Blood Stem Cell Transplantation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

